iShares US Pharmaceuticals ETF
96 hedge funds and large institutions have $96.6M invested in iShares US Pharmaceuticals ETF in 2018 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 30 reducing their positions, and 16 closing their positions.
269% more call options, than puts
Call options by funds: $3.01M | Put options by funds: $816K
2% less funds holding
Funds holding: 98 → 96 (-2)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
16.73% less ownership
Funds ownership: 97.45% → 80.72% (-17%)
23% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 30
35% less capital invested
Capital invested by funds: $148M → $96.6M (-$51.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Colony Group
Boston,
Massachusetts
|
+$8.56M |
| 2 |
BW
Biegel & Waller
Columbia,
Maryland
|
+$5.91M |
| 3 |
FWCM
Ferguson Wellman Capital Management
Portland,
Oregon
|
+$1.62M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$1.26M |
| 5 |
Mawer Investment Management
Calgary,
Alberta, Canada
|
+$1.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$34.3M |
| 2 |
CIBC World Market
Toronto,
Ontario, Canada
|
-$4.11M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$2.68M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.44M |
| 5 |
Jane Street
New York
|
-$1.39M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NA
101
NewEdge Advisors
New Orleans,
Louisiana
| – | -$309K | -5,520 | Closed |
|
|
TFA
102
Toth Financial Advisory
Leesburg,
Virginia
| – | -$244K | -4,365 | Closed |
|
|
NFC
103
Northeast Financial Consultants
Westport,
Connecticut
| – | -$231K | -4,140 | Closed |
|
104
Janney Montgomery Scott
Philadelphia,
Pennsylvania
| – | -$228K | -4,071 | Closed |
|
|
MGIA
105
Matthew Goff Investment Advisor
Houston,
Texas
| – | -$202K | -3,615 | Closed |
|
|
AFG
106
Arkansas Financial Group
Little Rock,
Arkansas
| – | -$200K | -3,588 | Closed |
|
|
SWP
107
Stratos Wealth Partners
Beachwood,
Ohio
| – | -$158K | -2,817 | Closed |
|
|
SWMG
108
Signature Wealth Management Group
Atlanta,
Georgia
| – | -$47K | -933 | Closed |
|
|
ICM
109
IMS Capital Management
Portland,
Oregon
| – | -$17K | -300 | Closed |
|
|
CAG
110
Csenge Advisory Group
Clearwater,
Florida
| – | -$13K | -270 | Closed |
|
|
TPWA
111
TRUE Private Wealth Advisors
Salem,
Oregon
| – | -$6.73K | -120 | Closed |
|
IHE Hedge Fund Activity: Q4 2018 in Review
96 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q4 2018, worth a combined $96.6M — down 35% from $148M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of IHE and 14 opened new positions — a net loss of 2 holders — while 30 trimmed existing stakes and 23 added.
The largest buyer was Colony Group, opening a new position worth an estimated $8.56M. The largest seller was Morgan Stanley, cutting an estimated $34.3M.
- 96 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q4 2018, down from 98 in Q3 2018.
- Funds reported $96.6M of iShares US Pharmaceuticals ETF stock for Q4 2018, down 35% quarter-over-quarter.
- 14 funds opened new iShares US Pharmaceuticals ETF positions in Q4 2018 and 16 closed out, a net change of -2 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q4 2018 was Colony Group, an estimated $8.56M added.
- The largest iShares US Pharmaceuticals ETF seller in Q4 2018 was Morgan Stanley, an estimated $34.3M sold.
Based on aggregated 13F filings for Q4 2018.